Author

Marcus Otho Butler

University Health NetworkORCID 0000-0002-9840-7057Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Mark David MindeniD· 3 shared Brian D. BurtiD· 2 shared Dalam LyiD· 2 shared Dong-Hoon HaniD· 2 shared Evey Y. F. ZhengiD· 2 shared Fumie IharaiD· 2 shared Kayoko SasoiD· 2 shared Naoto HiranoiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Mark David MindenORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Exploiting HLA-II Promiscuity via Peptide Terminal Overhang Recognition for Pan-Allelic and Tumor-Selective AML Immunotherapy

Saori Fukao, Evey Y. F. Zheng, Fumie Ihara, Yukiko Matsunaga, Yota Ohashi, Dong-Hoon Han, Xinyu Wei, Kana Hasegawa, Brian D. Burt, Kayoko Saso, Dalam Ly, Marcus Otho Butler, Mark David Minden, Yuki Kagoya, Naoto Hirano

This paper identifies an MPO-derived epitope promiscuously presented by HLA-II molecules and develops a pan-allelic antibody that selectively targets AML cells while sparing normal myeloid cells.

bioRxiv · Mar 3, 2026 · PreprintImmunology

Hematopoietic Tet2 inactivation enhances the response to checkpoint blockade immunotherapy

Vincent Rondeau, Suraj Bansal, Marco M. Buttigieg, Andy G.X. Zeng, Darryl Y. Chan, Michelle Chan‐Seng‐Yue, Jin Liqing, Jessica L. McLeod, Meghan Kates, Elisa Donato, Patrick Stelmach, Caitlyn Vlasschaert, Yitong Yang, Aarushi Gupta, Sofia Genta, , Robert J. Vanner

This study shows that hematopoietic Tet2 inactivation improves immune checkpoint blockade response in mice and is associated with better clinical outcomes in melanoma patients with TET2-driven clonal hematopoiesis.

Cancer Research · Nov 11, 2025Peer-reviewedCancer Biology

Peptide-Specific CAR T cells Recognize WT1 Promiscuously Presented by Diverse HLA Class II Alleles

Chung-Hsi Wang, Evey Y. F. Zheng, Toshiki Ochi, Yota Ohashi, Fumie Ihara, Saori Fukao, Giselle M. Boukhaled, Ben X. Wang, Dong-Hoon Han, Xinyu Wei, Brian D. Burt, Kayoko Saso, Yukiko Matsunaga, Dalam Ly, Yuki Kagoya, , Naoto Hirano

This paper develops WT1-specific CAR T cells that recognize the WT1330-348 peptide across 18 HLA-II alleles, enabling broad therapeutic application.

bioRxiv · Jun 30, 2025 · PreprintImmunology